Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib. Wei Q, Xu J. Blood 2024;144:238.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wei Q, Xu J. Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib. Blood 2024;144:238.
PMID: 38990537